Madrigal Pharmaceuticals, Inc.
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About MDGL
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Find out what a historical investment in Madrigal Pharmaceuticals, Inc. would be worth today using our MDGL stock calculator.
$6.66B
-
0.00%
145.92K
$300.00
$276.20
$299.26
$377.46
$189.00
Ready to start your investing journey with Stake?
Open an accountMDGL FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in MDGL
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in MDGL
on Stake
Buy MDGL from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of MDGL from only US$10 with fractional shares
